This report was first published by Endpoints News. To see the original version, click here
SpyGlass Pharma and Agomab Therapeutics filed for initial public offerings on Friday evening.
The drug developers hope to build on the strong start set by Aktis Oncology’s $318 million Nasdaq listing last Friday. They joined the queue a week after cancer drug developer Eikon Therapeutics and hair growth biotech Veradermics revealed their IPO ambitions.
您已阅读14%（443字），剩余86%（2720字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。